A Study Comparing the Efficacy of TA103 and the Placebo Control in the Treatment of Interdigital … (NCT04883593) | Clinical Trial Compass
CompletedEarly Phase 1
A Study Comparing the Efficacy of TA103 and the Placebo Control in the Treatment of Interdigital Tinea Pedis.
United States160 participantsStarted 2020-09-03
Plain-language summary
To evaluate and compare the safety and efficacy of TA103 in the treatment of tinea pedis.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Healthy male or non pregnant female aged ≥ 18 years
* Subjects must have provided IRB approved written informed consent
* Subjects must have clinical diagnosis of interdigital tinea pedis with lesions localized to the interdigital spaces or predominantly interdigital, but may extend to other areas of the foot (the non-interdigital lesions should not be hyperkeratotic, i.e., characteristic of tinea pedis moccasin).
Exclusion Criteria:
* Female Subjects who are pregnant, nursing or planning to become pregnant during study participation.
* Subjects with a history of hypersensitivity or allergy to any of the study medication ingredients and its excipients.
* Confluent, diffuse moccasin-type tinea pedis of the entire plantar surface.
What they're measuring
1
The proportion of subjects with complete cure at Week 6 (+/- 4 days) following treatment (study day 38-46)